Residency · Residency · Diagnostic Radiology
Rectal Cancer Staging: MRI-Based Assessment
Introduction
High-resolution pelvic MRI is the cornerstone of rectal cancer staging and plays a critical role in treatment planning. Accurate MRI assessment of tumor depth, nodal involvement, mesorectal fascia (MRF) status, and extramural vascular invasion (EMVI) directly determines whether a patient receives neoadjuvant chemoradiation prior to surgery or proceeds directly to total mesorectal excision (TME).
Anatomy Relevant to Staging
The rectum extends approximately 15 cm from the anal verge to the rectosigmoid junction and is divided into lower (0-5 cm), middle (5-10 cm), and upper (10-15 cm) segments. The mesorectal fascia (MRF) is the fascial envelope surrounding the mesorectum and defines the circumferential resection margin (CRM) in TME surgery. The muscularis propria, consisting of inner circular and outer longitudinal smooth muscle layers, is the key landmark for T staging. The intersphincteric plane and levator ani are critical landmarks for low rectal tumors.
MRI Protocol
Technical Requirements
High-resolution T2-weighted sequences are the primary staging sequences. Thin-slice (3 mm) oblique axial images perpendicular to the tumor long axis are essential. Sagittal and coronal planes allow tumor localization and assessment of the relationship to the anal sphincter complex. Diffusion-weighted imaging (DWI) improves detection of tumor and lymph nodes. The field of view should include the entire pelvis from the promontory to the perineum.
Post-Treatment MRI
Post-treatment MRI is performed 6-8 weeks after completion of neoadjuvant chemoradiation for assessment of treatment response and restaging (ymrT and ymrN). DWI is particularly valuable for identifying residual viable tumor within fibrotic tissue.
T Staging
| T Stage | Description | Substage (T3) |
|---|---|---|
| T1 | Confined to submucosa | -- |
| T2 | Invades muscularis propria, not beyond | -- |
| T3 | Extends through muscularis into mesorectal fat | T3a: <1 mm; T3b: 1-5 mm; T3c: 5-15 mm; T3d: >15 mm |
| T4a | Invades visceral peritoneum | -- |
| T4b | Invades adjacent organs/structures | -- |
T1 indicates tumor confined to the submucosa (T1 and early T2 may be candidates for local excision). T2 indicates tumor invading the muscularis propria but not extending beyond it. T3 indicates tumor extending through the muscularis propria into the mesorectal fat, subclassified by depth of extramural spread: T3a (less than 1 mm), T3b (1-5 mm), T3c (5-15 mm), and T3d (greater than 15 mm). T4a indicates tumor invading the visceral peritoneum, and T4b indicates tumor invading adjacent organs or structures. MRI has difficulty distinguishing T1 from T2; endorectal ultrasound may be preferred for early tumors.
Circumferential Resection Margin
The CRM is the shortest distance from the outermost tumor edge (or involved lymph node) to the MRF. A threatened CRM has a distance of 1-2 mm to the MRF. An involved CRM means tumor or an involved node is within 1 mm of or extending to the MRF. A positive or threatened CRM predicts high local recurrence risk and typically indicates the need for neoadjuvant therapy. The CRM distance and clock-face position of the closest approach should be reported.
N Staging
Nodal Assessment
Lymph node size alone is unreliable; morphologic criteria are more important. Suspicious features include mixed signal intensity, irregular border, and round shape. Nodes larger than 9 mm in short axis are suspicious by size criteria alone. Nodes in the mesorectum, along the superior rectal artery, and in the internal iliac chains should be evaluated. Lateral pelvic lymph nodes (obturator, internal iliac) in low rectal tumors carry prognostic significance.
Extramural Vascular Invasion (EMVI)
EMVI is identified as tumor signal extending into the mesorectal veins on T2-weighted images, appearing as nodular or serpiginous tumor signal within or expanding a vessel. It is a strong predictor of distant metastatic disease and poor prognosis. It should be reported as present, absent, or indeterminate. EMVI-positive patients may benefit from intensified systemic therapy.
Response Assessment After Neoadjuvant Therapy
MRI Tumor Regression Grading (mrTRG)
| mrTRG | Description | Response |
|---|---|---|
| 1 | Signal void or thin linear scar, no residual tumor | Complete regression |
| 2 | Dense fibrosis, minimal residual tumor signal | Good response |
| 3 | Mixed fibrosis and tumor signal (~50:50) | Moderate response |
| 4 | Minimal fibrosis, predominantly tumor signal | Slight response |
| 5 | No evidence of regression | No response |
mrTRG 1 indicates complete regression (signal void or thin linear scar with no residual tumor signal). mrTRG 2 indicates dense fibrosis with minimal residual tumor signal. mrTRG 3 indicates mixed fibrosis and tumor signal (approximately 50:50). mrTRG 4 indicates minimal fibrosis with predominantly tumor signal. mrTRG 5 indicates no evidence of regression. Complete clinical response may qualify patients for watch-and-wait (organ-preservation) protocols.
Key Clinical Pearls
Always report the CRM distance, T stage with extramural depth, N stage with morphologic criteria, and EMVI status; these four elements drive treatment decisions. MRI cannot reliably distinguish T1 from T2; refer early tumors for endorectal ultrasound assessment. T3 substaging by extramural depth is clinically important: T3a/b tumors with clear CRM may proceed to surgery, while T3c/d or threatened CRM typically receive neoadjuvant therapy. DWI is essential for post-treatment restaging; high DWI signal in a treated bed suggests residual viable tumor.
References
- Beets-Tan RGH, et al. Magnetic resonance imaging for clinical management of rectal cancer: updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol. 2018;28(4):1465-1475.
- MERCURY Study Group. Diagnostic accuracy of preoperative MRI in predicting curative resection of rectal cancer. BMJ. 2006;333(7572):779.
- Taylor FGM, et al. Preoperative MRI assessment of circumferential resection margin predicts disease-free survival. Br J Surg. 2011;98(6):872-879.
- Patel UB, et al. MRI after treatment of locally advanced rectal cancer. Radiology. 2012;263(1):132-139.